Respiratory Syncytial Virus (RSV) Vaccination Coverage, Adults 60 years and older, United States

  • Respiratory Syncytial Virus (RSV) vaccination coverage for adults is assessed through U.S. jurisdictions’ Immunization Information Systems (IIS) data, submitted from jurisdictions to CDC monthly in aggregate by age group.
  • RSV vaccination coverage estimate numerators include the number of people receiving at least one dose of an RSV vaccine since July 2023, based on information that state, territorial, and local public health agencies report to CDC. Some jurisdictions may report data submitted by tribes. Estimates include persons who are deceased but received a vaccination during the current season. People receiving doses are attributed to the jurisdiction in which the person resides unless noted otherwise. Quality and completeness of data may vary across jurisdictions. RSV vaccination coverage denominators are obtained from 2020 U.S. Census Bureau population estimates.
  • Monthly estimates shown are cumulative, reflecting all persons vaccinated from July 2023 through the end of the reporting month. Cumulative estimates include any historical data reported since the previous submission. National estimates are not presented since not all U.S. jurisdictions are currently reporting their IIS data to CDC. Jurisdictions reporting data to CDC include U.S. states, some localities, and territories.
  • Because IIS data are intended to capture all vaccinations administered within a jurisdiction rather than a sample, standard errors were not calculated.
  • Laws and policies regarding the submission of vaccination data to an IIS vary by state, which may impact the completeness of vaccination coverage reflected for a jurisdiction.
  • Coverage estimates based on IIS data are expected to differ from National Immunization Survey (NIS) estimates for adults. NIS estimates are based on a sample that may not be representative after survey weighting, and vaccination status is determined by survey respondent rather than vaccine records or administrations. Quality and completeness of IIS data may vary across jurisdictions. In general, NIS estimates tend to overestimate coverage due to overreporting and IIS estimates may underestimate coverage due to incompleteness of data in certain jurisdictions.
  • IIS coverage estimates reported on jurisdictions’ dashboards may use different criteria for numerators and denominators (e.g. jurisdictions may use IIS-based denominator instead of census population) and thus IIS estimates may differ from those reported on CDC’s Weekly RSV Vaccination dashboard.
  • Figure 2A. Monthly Cumulative Number and Percent of Adults 60 Years and Older Who Received 1+ RSV Vaccination Doses*, by Jurisdiction, United States​. Data Source: U.S. Jurisdiction Immunization Information Systems (IIS). Data are current through March 31, 2024.
  • Figure 2B. Monthly Cumulative Number and Percent of Adults 60 Years and Older Who Received 1+ RSV Vaccination Doses*, by Jurisdiction, United States​. Data Source: U.S. Jurisdiction Immunization Information Systems (IIS). Data are current through March 31, 2024.
View and Download Data for Fig. 2

*These data include both valid and invalid doses, persons with last known addresses in the jurisdiction, and persons with unknown addresses within the jurisdiction. Data excludes people whom a provider has indicated have left the jurisdiction. RSV vaccination coverage was calculated among adults aged 60 years or older as of September 30, 2023. Number of doses administered, and coverage estimates for a given month may change over time for some jurisdictions. New York City (New York) and Philadelphia (Pennsylvania) report data separately from their respective states. New York state data exclude New York City and Pennsylvania state data exclude Philadelphia County.

Figure 2A (line graph) will not display any lines for jurisdictions whose data have not been submitted to CDC; these jurisdictions appear gray in the Figures 2B. Some Pacific Island jurisdictions’ vaccination programs may be aligned to regional virus circulation patterns (i.e., they may vaccinate on a different schedule than the continental U.S.).